LEGEND BIOTECH CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.36 USD | -7.61% |
|
-14.25% | -33.92% |
| May. 22 | MaxCyte inks deal with Legend Biotech for tech supply | AN |
| May. 22 | MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program | MT |
Financials (USD)
| Sales 2024 * | 538M | Sales 2025 * | 1.06B | Capitalization | 7.77B |
|---|---|---|---|---|---|
| Net income 2024 * | -313M | Net income 2025 * | -129M | EV / Sales 2024 * | 13.2 x |
| Net cash position 2024 * | 648M | Net cash position 2025 * | 787M | EV / Sales 2025 * | 6.59 x |
| P/E ratio 2024 * |
-43.6
x | P/E ratio 2025 * |
-94.9
x | Employees | 2,000 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Legend Biotech Corporation
More recommendations
More press releases
More news
| 1 day | -5.83% | ||
| 1 week | -12.75% | ||
| Current month | -7.50% | ||
| 1 month | -14.73% | ||
| 3 months | -38.79% | ||
| 6 months | -33.11% | ||
| Current year | -32.76% |
1 week
40.28
46.52
1 month
40.2848.55
Current year
40.2870.13
1 year
40.2877.32
3 years
30.7677.32
5 years
23.4177.32
10 years
23.4177.32
| Managers | Title | Age | Since |
|---|---|---|---|
Ying Huang
CEO | Chief Executive Officer | 51 | 19-06-30 |
Lori Macomber
DFI | Director of Finance/CFO | 53 | 19-08-31 |
Tracy Luo
CTO | Chief Tech/Sci/R&D Officer | - | 18-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ying Huang
CEO | Chief Executive Officer | 51 | 19-06-30 |
Corazon Sanders
BRD | Director/Board Member | 67 | 20-04-30 |
Li Zhu
BRD | Director/Board Member | 74 | 20-11-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.08% | 4 M€ | -27.92% | ||
| 1.18% | 2 M€ | -14.14% | ||
| 0.99% | 2 M€ | -15.43% | - | |
| 0.95% | 11 M€ | -6.03% | - | |
| 0.58% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 39.62 | -7.00% | 977 709 |
| 24-05-22 | 42.6 | -0.84% | 855,054 |
| 24-05-21 | 42.96 | -5.44% | 930,117 |
| 24-05-20 | 45.43 | +0.60% | 732,550 |
| 24-05-17 | 45.16 | -2.61% | 566,508 |
Delayed Quote Nasdaq, May 23, 2024 at 11:26 am EDT
More quotes
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Calendar
2024-08-29
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
42.6
USD
Average target price
85.2
USD
Spread / Average Target
+100.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.76% | 7.77B | |
| +10.58% | 115B | |
| +12.74% | 106B | |
| -4.61% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -11.05% | 17.56B | |
| -39.36% | 17.32B | |
| +6.81% | 14.03B | |
| +32.64% | 12.13B |
- Stock Market
- Equities
- LEGN Stock
